LYSVENURE Trademark

Trademark Overview

On Wednesday, February 17, 2021, a trademark application was filed for LYSVENURE with the United States Patent and Trademark Office. The USPTO has given the LYSVENURE trademark a serial number of 90531828. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 28, 2024. This trademark is owned by Genzyme Corporation. The LYSVENURE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of cardiovascular diseases and diseases of the central nervous system; pharmaceutical preparations for the treatment of cancer, thrombosis, and respiratory diseases; pharmaceutical preparations for the treatment of rare diseases, namely, lysosomal storage disorders and autosomal dominant polycystic kidney disease; pharmaceutical preparations for the prevention and treatment of infectious diseases, namely, viral and bacterial infections
lysvenure

General Information

Serial Number90531828
Word MarkLYSVENURE
Filing DateWednesday, February 17, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 28, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 27, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for the prevention and treatment of cardiovascular diseases and diseases of the central nervous system; pharmaceutical preparations for the treatment of cancer, thrombosis, and respiratory diseases; pharmaceutical preparations for the treatment of rare diseases, namely, lysosomal storage disorders and autosomal dominant polycystic kidney disease; pharmaceutical preparations for the prevention and treatment of infectious diseases, namely, viral and bacterial infections

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, May 19, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGenzyme Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142
Party NameGenzyme Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events

Event DateEvent Description
Saturday, February 20, 2021NEW APPLICATION ENTERED
Wednesday, May 19, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sunday, June 20, 2021ASSIGNED TO EXAMINER
Tuesday, June 22, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 7, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 27, 2021PUBLISHED FOR OPPOSITION
Tuesday, July 27, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 21, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, February 10, 2022SOU TEAS EXTENSION RECEIVED
Thursday, February 10, 2022SOU EXTENSION 1 FILED
Thursday, February 10, 2022SOU EXTENSION 1 GRANTED
Saturday, February 12, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, September 1, 2022SOU TEAS EXTENSION RECEIVED
Thursday, September 1, 2022SOU EXTENSION 2 FILED
Thursday, September 1, 2022SOU EXTENSION 2 GRANTED
Saturday, September 3, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 25, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, January 25, 2023SOU EXTENSION 3 FILED
Wednesday, January 25, 2023SOU EXTENSION 3 GRANTED
Friday, January 27, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 7, 2023SOU TEAS EXTENSION RECEIVED
Monday, August 7, 2023SOU EXTENSION 4 FILED
Monday, August 7, 2023SOU EXTENSION 4 GRANTED
Wednesday, August 9, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 30, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, January 30, 2024SOU EXTENSION 5 FILED
Monday, February 12, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, February 12, 2024SOU EXTENSION 5 GRANTED
Tuesday, February 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 28, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, October 28, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

lysvenure diseases pharmaceutical treatment preparations prevention namely polycystic autosomal kidney dominant